Here are the 10-K annual reports from Celularity Inc. (CELU) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CELU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CELU filings page.
Celularity Inc. amended its 2025 annual report solely to add Part III disclosures covering directors, executive compensation, ownership, related-party transactions and auditor fees; it says the amendment does not otherwise update the original report.
The disclosures describe a financing for up to $25.0 million in aggregate principal amount of senior secured convertible promissory notes, together with warrants. At the initial closing, the Philip & Daniele Barach Family Trust’s existing $3.0 million convertible note was amended and restated with a $1.50 per-share conversion price; its related warrant covers up to 1,258,740 shares at a $1.50 per-share exercise price. A portion of the proceeds repaid amounts outstanding under the Trust’s June 2026 secured loan and obtained release of its security interest. Philip A. Barach joined the board effective September 24, 2026.
The five-member board identified Peter H. Diamandis and Diane Parks as independent; Robert J. Hariri, Steven N. Gordon and Philip A. Barach were not independent. The committee-exception discussion for Mr. Barach retains bracketed prompts for the board’s specific rationale. Audit fees were $705,075 for 2025 and $519,750 for 2024.
Celularity Inc. files an annual report describing a placenta-based cellular and regenerative medicine business alongside commercial biomaterials and biobanking operations. The company develops off‑the‑shelf placental cell therapies and advanced wound-care biomaterials, and also provides contract manufacturing and development services from a 147,215 square foot Florham Park, New Jersey facility.
As of December 31, 2025, Celularity had cash and cash equivalents of $6.2 million and reported a net loss of $91.7 million for 2025, with an accumulated deficit of $991.5 million, raising substantial doubt about its ability to continue as a going concern. Management states it must obtain additional capital through equity, debt or strategic transactions to fund operations beyond the next 12 months and notes recent headcount and salary reductions in early 2026 to conserve cash. The company’s current revenues come primarily from biomaterials and biobanking, and it is prioritizing longevity‑focused placental cell therapies, expansion of its biomaterials pipeline and licensing or partnering older cell‑therapy assets.